{"entity":{"type":"insider","cik":"0001979548","url":"/insider/0001979548","json_url":"/insider/0001979548.json","name":"ARCH Venture Partners XII, LLC","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":25,"n_filings":12,"first":"2023-09-20","last":"2026-05-04","span_basis":"filed_date"},"name_variants":[{"name":"ARCH Venture Partners XII, LLC","source":"filing","n_filings":12,"first_seen":"2023-09-20","last_seen":"2026-05-04"}],"transactions":[{"id":6017298,"accession":"0001193125-26-204458","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001193125-26-204458","line_url":"/filing/0001193125-26-204458#line-3","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Seaport Therapeutics, Inc.","issuer_ticker":"SPTX","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"ARCH Venture Fund XII, L.P.; ARCH Venture Partners XII, L.P.; ARCH Venture Partners XII, LLC; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT","owner_display_name":"ARCH Venture Fund XII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1100000.0,"shares_display":"1,100,000","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":19800000.0,"total_display":"19,800,000.00","total_whole":"19,800,000","shares_owned_after":6294951.0,"shares_owned_after_display":"6,294,951","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-05-04","filed_date":"2026-05-04","scope":"insider"},{"id":4314484,"accession":"0001012975-25-000680","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001012975-25-000680","line_url":"/filing/0001012975-25-000680#line-1","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"GILLIS STEVEN; ARCH Venture Fund XII, L.P.; ARCH Venture Partners XII, L.P.; ARCH Venture Partners XII, LLC; CRANDELL KEITH; NELSEN ROBERT; BYBEE CLINTON","owner_display_name":"GILLIS STEVEN","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1915700.0,"shares_display":"1,915,700","price_per_share":2.61,"price_display":"2.61","price_state":"stated","total_value":4999977.0,"total_display":"4,999,977.00","total_whole":"4,999,977","shares_owned_after":6046907.0,"shares_owned_after_display":"6,046,907","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-10-27","filed_date":"2025-10-29","scope":"insider"},{"id":4762490,"accession":"0001062993-25-013461","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-25-013461","line_url":"/filing/0001062993-25-013461#line-1","is_derivative":false,"issuer_cik":"0001894562","issuer_name":"Prime Medicine, Inc.","issuer_ticker":"PRME","issuer_name_source":null,"issuer_url":"/issuer/0001894562","owner_cik":null,"owner_name":"ARCH Venture Partners XII, LLC; ARCH Venture Partners XII, L.P.; ARCH Venture Fund XII, L.P.","owner_display_name":"ARCH Venture Partners XII, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3030300.0,"shares_display":"3,030,300","price_per_share":3.3,"price_display":"3.30","price_state":"stated","total_value":9999990.0,"total_display":"9,999,990.00","total_whole":"9,999,990","shares_owned_after":6230300.0,"shares_owned_after_display":"6,230,300","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-01","filed_date":"2025-08-01","scope":"insider"},{"id":4027194,"accession":"0000950170-25-012579","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-25-012579","line_url":"/filing/0000950170-25-012579","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Metsera, Inc.","issuer_ticker":"MTSR","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"ARCH Venture Fund XII, L.P.; ARCH Venture Fund XIII, L.P.; ARCH Venture Partners XII, L.P.; ARCH Venture Partners XII, LLC; ARCH Venture Partners XIII, L.P.; ARCH Venture Partners XIII, LLC; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT","owner_display_name":"ARCH Venture Fund XII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2222222.0,"shares_display":"2,222,222","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":39999996.0,"total_display":"39,999,996.00","total_whole":"39,999,996","shares_owned_after":18503128.0,"shares_owned_after_display":"18,503,128","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-02-03","filed_date":"2025-02-03","scope":"insider","n_lines":2},{"id":2553280,"accession":"0001062993-24-003739","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-24-003739","line_url":"/filing/0001062993-24-003739#line-1","is_derivative":false,"issuer_cik":"0001894562","issuer_name":"Prime Medicine, Inc.","issuer_ticker":"PRME","issuer_name_source":null,"issuer_url":"/issuer/0001894562","owner_cik":null,"owner_name":"ARCH Venture Partners XII, LLC; ARCH Venture Fund XII, L.P.; ARCH Venture Partners XII, L.P.","owner_display_name":"ARCH Venture Partners XII, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3200000.0,"shares_display":"3,200,000","price_per_share":6.25,"price_display":"6.25","price_state":"stated","total_value":20000000.0,"total_display":"20,000,000.00","total_whole":"20,000,000","shares_owned_after":3200000.0,"shares_owned_after_display":"3,200,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-02-15","filed_date":"2024-02-20","scope":"insider"},{"id":8318199,"accession":"0001062993-23-020933","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001062993-23-020933","line_url":"/filing/0001062993-23-020933#line-2","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"GILLIS STEVEN; NELSEN ROBERT; ARCH Venture Partners XII, LLC; CRANDELL KEITH; ARCH Venture Partners XII, L.P.; ARCH Venture Fund XII, L.P.","owner_display_name":"GILLIS STEVEN","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3357.0,"shares_display":"3,357","price_per_share":11.98,"price_display":"11.98","price_state":"stated","total_value":40216.86,"total_display":"40,216.86","total_whole":"40,217","shares_owned_after":4131207.0,"shares_owned_after_display":"4,131,207","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-14","filed_date":"2023-11-15","scope":"insider"},{"id":8318196,"accession":"0001062993-23-020933","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-23-020933","line_url":"/filing/0001062993-23-020933#line-1","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"GILLIS STEVEN; NELSEN ROBERT; ARCH Venture Partners XII, LLC; CRANDELL KEITH; ARCH Venture Partners XII, L.P.; ARCH Venture Fund XII, L.P.","owner_display_name":"GILLIS STEVEN","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":31653.0,"shares_display":"31,653","price_per_share":11.75,"price_display":"11.75","price_state":"stated","total_value":371922.75,"total_display":"371,922.75","total_whole":"371,923","shares_owned_after":4127850.0,"shares_owned_after_display":"4,127,850","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-13","filed_date":"2023-11-15","scope":"insider"},{"id":7859638,"accession":"0001062993-23-020712","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001062993-23-020712","line_url":"/filing/0001062993-23-020712","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"NELSEN ROBERT; ARCH Venture Partners XII, LLC; CRANDELL KEITH; ARCH Venture Fund XII, L.P.; ARCH Venture Partners XII, L.P.; GILLIS STEVEN","owner_display_name":"NELSEN ROBERT","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":17275.0,"shares_display":"17,275","price_per_share":11.489466280752533,"price_display":"11.49","price_state":"stated","total_value":198480.53,"total_display":"198,480.53","total_whole":"198,481","shares_owned_after":4090766.0,"shares_owned_after_display":"4,090,766","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-10","filed_date":"2023-11-13","scope":"insider","n_lines":2},{"id":7859631,"accession":"0001062993-23-020712","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001062993-23-020712","line_url":"/filing/0001062993-23-020712#line-3","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"NELSEN ROBERT; ARCH Venture Partners XII, LLC; CRANDELL KEITH; ARCH Venture Fund XII, L.P.; ARCH Venture Partners XII, L.P.; GILLIS STEVEN","owner_display_name":"NELSEN ROBERT","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":31079.0,"shares_display":"31,079","price_per_share":10.53,"price_display":"10.53","price_state":"stated","total_value":327261.87,"total_display":"327,261.87","total_whole":"327,262","shares_owned_after":4078922.0,"shares_owned_after_display":"4,078,922","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-09","filed_date":"2023-11-13","scope":"insider"},{"id":7859629,"accession":"0001062993-23-020712","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001062993-23-020712","line_url":"/filing/0001062993-23-020712","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"NELSEN ROBERT; ARCH Venture Partners XII, LLC; CRANDELL KEITH; ARCH Venture Fund XII, L.P.; ARCH Venture Partners XII, L.P.; GILLIS STEVEN","owner_display_name":"NELSEN ROBERT","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":92251.0,"shares_display":"92,251","price_per_share":11.033170588936706,"price_display":"11.03","price_state":"stated","total_value":1017821.02,"total_display":"1,017,821.02","total_whole":"1,017,821","shares_owned_after":4024719.0,"shares_owned_after_display":"4,024,719","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-08","filed_date":"2023-11-13","scope":"insider","n_lines":2},{"id":8140002,"accession":"0001062993-23-020279","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001062993-23-020279","line_url":"/filing/0001062993-23-020279#line-3","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"GILLIS STEVEN; NELSEN ROBERT; ARCH Venture Fund XII, L.P.; ARCH Venture Partners XII, LLC; CRANDELL KEITH; ARCH Venture Partners XII, L.P.","owner_display_name":"GILLIS STEVEN","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":30192.0,"shares_display":"30,192","price_per_share":11.5,"price_display":"11.50","price_state":"stated","total_value":347208.0,"total_display":"347,208.00","total_whole":"347,208","shares_owned_after":3955592.0,"shares_owned_after_display":"3,955,592","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-07","filed_date":"2023-11-07","scope":"insider"},{"id":8139998,"accession":"0001062993-23-020279","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001062993-23-020279","line_url":"/filing/0001062993-23-020279#line-2","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"GILLIS STEVEN; NELSEN ROBERT; ARCH Venture Fund XII, L.P.; ARCH Venture Partners XII, LLC; CRANDELL KEITH; ARCH Venture Partners XII, L.P.","owner_display_name":"GILLIS STEVEN","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":43082.0,"shares_display":"43,082","price_per_share":11.55,"price_display":"11.55","price_state":"stated","total_value":497597.1,"total_display":"497,597.10","total_whole":"497,597","shares_owned_after":3925400.0,"shares_owned_after_display":"3,925,400","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-06","filed_date":"2023-11-07","scope":"insider"},{"id":8139992,"accession":"0001062993-23-020279","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-23-020279","line_url":"/filing/0001062993-23-020279#line-1","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"GILLIS STEVEN; NELSEN ROBERT; ARCH Venture Fund XII, L.P.; ARCH Venture Partners XII, LLC; CRANDELL KEITH; ARCH Venture Partners XII, L.P.","owner_display_name":"GILLIS STEVEN","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":22420.0,"shares_display":"22,420","price_per_share":11.38,"price_display":"11.38","price_state":"stated","total_value":255139.6,"total_display":"255,139.60","total_whole":"255,140","shares_owned_after":3882318.0,"shares_owned_after_display":"3,882,318","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-03","filed_date":"2023-11-07","scope":"insider"},{"id":8402299,"accession":"0001062993-23-018632","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001062993-23-018632","line_url":"/filing/0001062993-23-018632#line-3","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"ARCH Venture Partners XII, L.P.; ARCH Venture Fund XII, L.P.; GILLIS STEVEN; NELSEN ROBERT; ARCH Venture Partners XII, LLC; CRANDELL KEITH","owner_display_name":"ARCH Venture Partners XII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":34560.0,"shares_display":"34,560","price_per_share":13.98,"price_display":"13.98","price_state":"stated","total_value":483148.8,"total_display":"483,148.80","total_whole":"483,149","shares_owned_after":3859898.0,"shares_owned_after_display":"3,859,898","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-09-29","filed_date":"2023-09-29","scope":"insider"},{"id":8402295,"accession":"0001062993-23-018632","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001062993-23-018632","line_url":"/filing/0001062993-23-018632","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"ARCH Venture Partners XII, L.P.; ARCH Venture Fund XII, L.P.; GILLIS STEVEN; NELSEN ROBERT; ARCH Venture Partners XII, LLC; CRANDELL KEITH","owner_display_name":"ARCH Venture Partners XII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":41951.0,"shares_display":"41,951","price_per_share":13.437089938261305,"price_display":"13.44","price_state":"stated","total_value":563699.36,"total_display":"563,699.36","total_whole":"563,699","shares_owned_after":3825338.0,"shares_owned_after_display":"3,825,338","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-09-28","filed_date":"2023-09-29","scope":"insider","n_lines":2},{"id":7890451,"accession":"0001062993-23-018547","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001062993-23-018547","line_url":"/filing/0001062993-23-018547#line-2","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"ARCH Venture Partners XII, L.P.; ARCH Venture Fund XII, L.P.; NELSEN ROBERT; ARCH Venture Partners XII, LLC; CRANDELL KEITH; GILLIS STEVEN","owner_display_name":"ARCH Venture Partners XII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":24504.0,"shares_display":"24,504","price_per_share":12.31,"price_display":"12.31","price_state":"stated","total_value":301644.24,"total_display":"301,644.24","total_whole":"301,644","shares_owned_after":3783387.0,"shares_owned_after_display":"3,783,387","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-09-27","filed_date":"2023-09-27","scope":"insider"},{"id":7890448,"accession":"0001062993-23-018547","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-23-018547","line_url":"/filing/0001062993-23-018547#line-1","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"ARCH Venture Partners XII, L.P.; ARCH Venture Fund XII, L.P.; NELSEN ROBERT; ARCH Venture Partners XII, LLC; CRANDELL KEITH; GILLIS STEVEN","owner_display_name":"ARCH Venture Partners XII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":34000.0,"shares_display":"34,000","price_per_share":11.73,"price_display":"11.73","price_state":"stated","total_value":398820.0,"total_display":"398,820.00","total_whole":"398,820","shares_owned_after":3758883.0,"shares_owned_after_display":"3,758,883","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-09-26","filed_date":"2023-09-27","scope":"insider"},{"id":8197807,"accession":"0001062993-23-018469","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001062993-23-018469","line_url":"/filing/0001062993-23-018469","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"NELSEN ROBERT; GILLIS STEVEN; ARCH Venture Fund XII, L.P.; ARCH Venture Partners XII, L.P.; ARCH Venture Partners XII, LLC; CRANDELL KEITH","owner_display_name":"NELSEN ROBERT","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":60740.0,"shares_display":"60,740","price_per_share":11.219360388541324,"price_display":"11.22","price_state":"stated","total_value":681463.95,"total_display":"681,463.95","total_whole":"681,464","shares_owned_after":3694916.0,"shares_owned_after_display":"3,694,916","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-09-25","filed_date":"2023-09-25","scope":"insider","n_lines":2},{"id":8197799,"accession":"0001062993-23-018469","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-23-018469","line_url":"/filing/0001062993-23-018469#line-1","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"NELSEN ROBERT; GILLIS STEVEN; ARCH Venture Fund XII, L.P.; ARCH Venture Partners XII, L.P.; ARCH Venture Partners XII, LLC; CRANDELL KEITH","owner_display_name":"NELSEN ROBERT","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":40000.0,"shares_display":"40,000","price_per_share":11.14,"price_display":"11.14","price_state":"stated","total_value":445600.0,"total_display":"445,600.00","total_whole":"445,600","shares_owned_after":3664143.0,"shares_owned_after_display":"3,664,143","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-09-22","filed_date":"2023-09-25","scope":"insider"},{"id":8280406,"accession":"0000899243-23-019274","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000899243-23-019274","line_url":"/filing/0000899243-23-019274#line-6","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"BYBEE CLINTON; ARCH Venture Partners X, LLC; GILLIS STEVEN; ARCH Venture Fund XII, L.P.; NELSEN ROBERT; ARCH Venture Partners XII, L.P.; ARCH Venture Partners XII, LLC; CRANDELL KEITH","owner_display_name":"BYBEE CLINTON","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1500000.0,"shares_display":"1,500,000","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":25500000.0,"total_display":"25,500,000.00","total_whole":"25,500,000","shares_owned_after":3624143.0,"shares_owned_after_display":"3,624,143","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-09-19","filed_date":"2023-09-20","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0002042347","name":"Seaport Therapeutics, Inc.","url":"/issuer/0002042347","role":"Ten percent owner","n_filings":1,"first_seen":"2026-05-04","last_seen":"2026-05-04"},{"type":"issuer","type_label":"ISSUER","cik":"0001885522","name":"Neumora Therapeutics, Inc.","url":"/issuer/0001885522","role":"Ten percent owner","n_filings":8,"first_seen":"2023-09-20","last_seen":"2025-10-29"},{"type":"issuer","type_label":"ISSUER","cik":"0001894562","name":"Prime Medicine, Inc.","url":"/issuer/0001894562","role":"Ten percent owner","n_filings":2,"first_seen":"2024-02-20","last_seen":"2025-08-01"},{"type":"issuer","type_label":"ISSUER","cik":"0002040807","name":"Metsera, Inc.","url":"/issuer/0002040807","role":"Ten percent owner","n_filings":1,"first_seen":"2025-02-03","last_seen":"2025-02-03"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001979548","retrieved_at":"2026-08-22T13:44:36+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}